for the development of ROA up to 10 years later. Future directions include developing a predictive model that incorporates multiple features.

Disclosure of Interests: C. Kent Kwok Grant/research support from: EMD Serono and Abbvie, Consultant for: EMD Serono, Fidia, Regulus, GSK, Taiwan Liposome Company, Inc, Kolon Tissue Gene, Express Scripts, Frank Roemer Shareholder of: Boston Imaging Core Lab (BICL), LLC., Leena Sharma: None declared, Erin Ashbeck Consultant for: EMD Serono, Chengcheng Hu: None declared, Ali Gueremazi Shareholder of: Boston Imaging Core Lab (BICL), LLC., Consultant for: Pfizer, AstraZeneca, MerckSerono, TissueGene, Galapagos and Roche

DOI: 10.1136/annrheumdis-2019-eular.4423

THURSDAY, 13 JUNE 2019

Different pathophysiological pathways in axial and peripheral disease: Peripheral and axial spondyloarthritis: to split or to lump?

OP0199

THE HUMAN ENTHESES HARBOURS RESIDENT ADAPTIVE CD4+ AND CD8+ T-CELLS WITH INDUCIBLE IL-17A AND TNF PROTEIN THAT IS PHARMACOLOGICALLY SUPPRESSED BY ROR γ T AND PDE4 INHIBITORS BUT NOT METHOTREXATE IN A NOVEL IN VITRO ENTHESTITIS MODEL

Abdulla Watad¹, Hannah Rowe², Charlie Bridgewood², Tobias Russell², Qiao Zhou², Almas Khan², Robert Dunsmuir², Peter Loughenbury², Abhay S Rao², Peter Millner², Richard Cuthbert², Dennis McGonagle². ¹Tel Aviv University, Tel Aviv-Yafo, Israel; ²University of Leeds, Leeds, United Kingdom

Background: Animal models have demonstrated that enthesitis is the primary lesion in experimental spondyloarthritis (SpA). In mice, innate lymphocytes were suggested as the major cytokine producers at the enthesis.

Objectives: We tested the hypothesis that the human entheses harbours tissue resident conventional T-cells. We also assessed their ability to express SpA-related cytokines including TNF and IL-17A and if this could be blocked using psoriasis therapeutic agents (methotrexate (MTX), and phosphodiesterase type 4 inhibitor (PDE4i)) and experimental ROR γ T inhibitors (ROR γ Ti).

Methods: Enthesal spinous process was obtained from patients undergoing elective orthopedic procedures (n=20) and mechanically digested or processed for confocal staining and flow cytometry. CD4+ and CD8+ T-cells were sorted and RNA was isolated and analysed by qPCR. Magnetically isolated cells were stimulated using an anti-CD3/CD2/CD28 bead with and without the presence of MTX, ROR γ Ti and PDE4i. Following stimulation IL-17A and TNF were measured by ELISA and intracellular flow cytometry.

Results: CD4+ and CD8+ T-cells represent 35.7% and 23.7% of T-cells in the entheses, respectively, with topographic confirmation by anti-CD3 immunofluorescence staining. Enthesal tissue contained a higher proportion of CD4+ and CD8+ T-cells expressing a resident memory phenotype (CD69+/CD45RA-) compared to matched blood. Sorted T-cells from enthesal tissue had a gene expression profile consistent with a tissue resident phenotype and CD4+ and CD8+ T-cells showed increased expression immunomodulatory genes including IL-10 and TGF- β compared to peripheral blood T-cells (p<0.001). Following stimulation CD4+ T-cells produced more TNF than CD8+ T-cells (p<0.05), IL-17A was robustly detected in CD4+ but not CD8+ T-cells. TNF and IL-17A production from CD4+ T-cells was effectively inhibited by PDE4i (p<0.05), while ROR γ Ti only reduced IL-17 secretion (p<0.001). MTX had no significant impact on both TNF and IL-17A production in either cell population. This pattern of inhibition was mirrored in TNF secretion from CD8+ T-cells.

Conclusion: This is the first description of conventional CD4+ and CD8+ entheses resident T-cells. PDE4i was effective in abrogating induced TNF production and IL-17, whereas ROR γ Ti is highly effective for IL-17A production but not TNF. In contrast, MTX had little effect on *in vitro* enthesitis model cytokine production. These findings may have some practical implications in the treatment of subclinical enthesitis.

Figure 1. Effect of different therapeutic agents on the TNF and IL-17A production by resident enthesal T-cells and matched peripheral blood

Figure 2. Gene expression profile of enthesal T-cells (soft tissue and adjacent bone) compared to peripheral blood

Abbreviations: ST, enthesal soft tissue; PEB, peri-enthesal bone.

Disclosure of Interests: Abdulla Watad: None declared, Hannah Rowe: None declared, Charlie Bridgewood: None declared, Tobias Russell Grant/research support from: PhD Project is funded by Novartis., Qiao Zhou: None declared, Almas Khan: None declared, Robert Dunsmuir: None declared, Peter Loughenbury: None declared, Abhay S Rao: None declared, Peter Millner: None declared, Richard Cuthbert: None declared, Dennis McGonagle Consultant for: Lilly, Novartis UCB, Speakers bureau: Lilly, Novartis UCB

DOI: 10.1136/annrheumdis-2019-eular.1087

OP0200

A SET OF INFLAMMATORY MARKERS ALLOWING TO DETECT SYSTEMIC INFLAMMATION IN PSORIATIC SKIN, ENTHESEAL AND JOINT DISEASE IN THE ABSENCE OF CRP AND THEIR LINK TO CLINICAL DISEASE MANIFESTATION

Maria Sokolova^{1,2}, Kemal Nas³, Yubin Luo⁴, David Simon¹, Yi Zhao⁴, Jürgen Rech¹, Mario Zaiss¹, Georg Schett¹. ¹Friedrich-Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany; ²Lomonosov Moscow State University, Faculty of Medicine, Moscow, Russian Federation; ³Sakarya University School of Medicine, Division of Rheumatology and Immunology, Sakarya, Turkey; ⁴West China Hospital, Sichuan University, Department of Rheumatology and Immunology, Chengdu, China

Background: Psoriatic disease is composed of skin, enthesal and joint disease, which can manifest isolated or combined. Little is known about the systemic inflammation levels in psoriatic disease as a robust IL-6 signal is missing and therefore acute phase reactants such as C-reactive protein are often normal. Measuring systemic inflammation in the different manifestations of psoriatic disease is therefore a continuous unmet need.

Objectives: To better define systemic inflammation in patients with psoriatic disease limited to the skin (S), the entheses (E) or the joints (arthritis, A) or with a combination of these disease manifestations (SE, SA, EA, SEA).

Methods: Hypothesis-driven approach selecting markers that are (i) either targets of IL-23/IL-17 pathway activation (b-defensin 2, lipocalin 2, IL-22), (ii) associated with neutrophil/monocyte activation (calprotectin, IL-8) and (iii) achieve serum concentrations sufficient for reliable detection by standard ELISA. Parameters were assessed in 210 individuals comprising 105 healthy controls and 105 patients with psoriatic disease (each 15 for isolated (S, E, A) and composed disease manifestations SE, SA, EA, SEA). Results are expressed as percent positive patients with levels above three standard deviations over the mean level in healthy controls. In addition, 6-months sequential data on levels of these markers were collected in 20 patients treated with secukinumab or adalimumab to test treatment effects.

Results: CRP levels were normal in the majority of individuals. The respective percentages of patients with normal CRP (<5mg/L) were as follows: S: 100%, E: 100%, A: 80%, SE: 93%, SA: 67%, EA: 73%, SEA: 67% (Figure). Thus, CRP is only elevated in a subset of patients with arthritis. In sharp contrast, beta-defensin 2 levels (>1.88 ng/mL) and lipocalin-2 (>24.7 ng/mL) were elevated in the majority of patients with isolated skin and enthesal, but not joint disease. Conversely, elevations of calprotectin (>3.58 mg/mL) and IL-8 (>10.3 pg/mL) were found in the majority of patients with isolated joint disease. IL-22 was elevated (>17.1 pg/mL) in all three manifestations of psoriatic disease. Reflecting a combination of the findings the vast majority of patients with composed disease manifestation (SE, SA, EA, SEA) showed widespread marker elevation. IL-17 and TNF inhibition differentially lowered and partially normalized elevated markers of inflammation.

Conclusion: Systemic inflammation is detectable in the majority of patients with psoriatic disease, even if CRP is normal. The respective marker pattern depends on the manifestation (skin, entheses, joints) of psoriatic disease, with beta-defensin 2 and lipocalin-2 reflecting skin and enthesal disease, calprotectin and IL-8 joint disease and IL-22 a combination of these disease manifestations.

Disclosure of Interests: Maria Sokolova Grant/research support from: M. Sokolova was a PARTNER Fellow, Celgene Säril, Kemal Nas: None declared, Yubin Luo: None declared, David Simon Grant/research support from: Novartis, Consultant for: Lilly, Speakers bureau: Janssen, Yi Zhao: None declared, Jürgen Rech Grant/research support from: Bristol-Myers Squibb and Celgene (greater than \$10,000), Consultant for: Bristol-Myers Squibb, Celgene, Chugai, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Roche, Sanofi Aventis, and UCB (in total more than \$10,000), Speakers bureau: Bristol-Myers Squibb, Celgene, Chugai, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Roche, Sanofi Aventis, and UCB (in total more than \$10,000), Mario Zaiss: None declared, Georg Schett: None declared

DOI: 10.1136/annrheumdis-2019-eular.4693

THURSDAY, 13 JUNE 2019

My joints hurt and I'm overwhelmingly tired – fatigue in rheumatoid arthritis

OP0201

FATIGUE IN JUVENILE IDIOPATHIC ARTHRITIS AFTER 18 YEARS OF FOLLOW-UP

Ellen Dalen Arnstad^{1,2}, Mia Glerup³, Veronika Rypdal^{4,5}, Suvi Peltoniemi⁶, Maria Ekelund^{7,8}, Lillemor Berntson⁹, Anders Fasth⁹, Susan Nielsen¹⁰, Marek Zak¹¹, Kristiina Aalto⁶, Ellen Nordal^{4,5}, Troels Herlin³, Pål Richard Romundstad¹², Marite Rygg^{2,13}. ¹Levanger Hospital, Dept. of Pediatrics, Levanger, Norway; ²NTNU – Norwegian University of Science and Technology, Dept. of Clin. and Molecular Med., Trondheim, Norway; ³Aarhus University Hospital, Dept. of Pediatrics, Aarhus, Denmark; ⁴University Hospital of North Norway, Dept. of Pediatrics, Tromsø, Norway; ⁵UiT The Arctic University of Norway, Dept. of Clin. Med., Tromsø, Norway; ⁶University of Helsinki, Helsinki, Finland; ⁷Ryhov County Hospital, Dept. of Pediatrics, Jönköping, Sweden; ⁸Uppsala University, Dept. of Women's and Children's Health, Uppsala, Sweden; ⁹Institute of Clin. Sciences, Sahlgrenska Academy, University of Gothenburg, Dept. of Pediatrics, Gothenburg, Sweden; ¹⁰Rigshospitalet Copenhagen University Hospital, Dept. of Pediatrics, Copenhagen, Denmark; ¹¹Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark; ¹²NTNU – Norwegian University of Science and Technology, Dept. of Public Health and Nursing, Trondheim, Norway; ¹³St. Olavs Hospital, Dept. of Pediatrics, Trondheim, Norway

Background: Fatigue is common in adults with rheumatic disease and has also been shown in adolescents with juvenile idiopathic arthritis (JIA). Knowledge on fatigue in JIA in long-term follow-up is limited.

Objectives: To study the prevalence and severity of fatigue 18 years after onset of JIA.

Methods: In this close to population-based cohort study from defined geographical areas of Norway, Sweden, Denmark and Finland, consecutive cases of JIA with disease onset in 1997 to 2000 were prospectively enrolled (1). At 18-year follow-up, fatigue was measured using Fatigue Severity Scale (FSS, range 0-7) (2), and severe fatigue was defined as FSS ≥4. General health status was measured with Health Assessment Questionnaire (HAQ) and 36-Item Short Form Health Survey (SF-36). Reduced health was defined as HAQ >0, and SF-36 <40 (according to the physical component summary score/mental component summary score (PCS/MCS)). Pain was measured with 10 cm visual analogue scale (VAS), 0 = no pain, >0 = pain. Remission was defined according to the preliminary criteria described by Wallace. A Norwegian healthy cohort was used for comparison. Multivariable logistic regression analyses were performed.

Results: Among 434 eligible JIA participants 377 completed a Fatigue Severity Scale (FSS) measurement at the 18-year follow-up and were included. Of these 72% were girls, 53% had oligoarticular disease six months after onset, median age at onset was 5.6 (IQR 2.6-9.7) years, and age at the 18-year visit was 23.1 (IQR 20.3-27.2). Mean total FSS (±SD) was 3.2 (±1.5), and participants with active disease scored 3.6 (±1.6) compared to 2.9 (±1.4) for those in remission off medication. The highest total FSS was found in those with SF-36 PCS and/or MCS <40 (4.7 (±1.6) and 4.6 (±1.6), respectively). Severe fatigue was considerably more frequent in participants with active disease (36%, odds ratio (OR) 2.5) compared to those in remission off medication (19%), HAQ score >0 (47%, OR 4.1) compared to HAQ score =0 (18%), SF-36 PCS/MCS <40 (64/61%, OR 7.1/6.9) compared to SF-36 PCS/MCS ≥40 (20/19%), and VAS pain >0 (36%, OR 3.8) compared to VAS pain =0 (13%). The proportion of severe fatigue in a healthy Norwegian control cohort was 12%.

Conclusion: At 18-year follow-up fatigue was a prominent symptom in JIA, and we found consistently higher fatigue burden and considerably more severe fatigue among participants with active disease, pain and self-reported health problems, compared to those without. We suggest fatigue to be measured at long-term follow-up both in clinical and research settings.

REFERENCES:

- [1] Nordal E, et al. Arthritis Rheum 2011;63:2809-18
- [2] Krupp LB, et al. Arch Neurol 1989;46:1121-23

Disclosure of Interests: Ellen Dalen Arnstad: None declared, Mia Glerup: None declared, Veronika Rypdal: None declared, Suvi Peltoniemi: None declared, Maria Ekelund: None declared, Lillemor Berntson Consultant for: AbbVie, Speakers bureau: AbbVie, Anders Fasth: None declared, Susan Nielsen: None declared, Marek Zak: None declared, Kristiina Aalto: None declared, Ellen Nordal: None declared, Troels Herlin: None declared, Pål Richard Romundstad: None declared, Marite Rygg: None declared

DOI: 10.1136/annrheumdis-2019-eular.4006